Year: 2026 | Month: February | Volume: 16 | Issue: 2 | Pages: 261-267
DOI: https://doi.org/10.52403/ijhsr.20260229
Real-World Evidence on the Clinical Effectiveness and Safety of Faropenem in the Management of Paediatric Upper Respiratory Tract Infections: A Multicentre Retrospective Study
Pushpak Palod1, Sumon Poddar2, Gajanan Dharmure3, Ajitkumar Gondane4, Amitrajit Pal4, Dattatray Pawar5, Akhilesh Sharma6
1Consultant Pediatrician, Anand Balrugnalay, Nashik, India
2Associate Professor, Institute of Child Health, Kolkata, India
3Consultant Pediatrician, Sai Children Hospital, Bhokar, Nanded, India
4Medical Advisor, Alkem Laboratories Ltd, Mumbai, India
5Medical Lead, Alkem Laboratories Ltd, Mumbai, India
6President and CMO, Alkem Laboratories Ltd, Mumbai, India
Corresponding Author: Dr. Ajitkumar Gondane
ABSTRACT
Objectives: To evaluate real-world evidence on the clinical effectiveness and safety of faropenem in the management of upper respiratory tract infections (URTIs) in Indian paediatric patients.
Methods: This multicentre, retrospective study analyzed medical records of paediatric patients (≤12 years) treated with faropenem oral suspension for URTIs. Records with complete and evaluable clinical data were included. Data collected comprised type of URTI, prescribed and actual duration of therapy, dosage and dosing frequency, laboratory parameters such as white blood cell (WBC) count and C-reactive protein (CRP) levels (where available), clinical outcomes, and adverse events. Assessments were conducted at baseline and follow-up, and results were analyzed using descriptive statistics.
Results: A total of 965 records (673 males; 292 females) were evaluated, with a mean age of 7.65 ± 2.87 years. Diagnoses included undifferentiated URTI (n=648), acute otitis media (n=142), tonsillitis (n=81), pharyngitis (n=79), and acute sinusitis (n=15). The mean prescribed and actual treatment durations were 5.96 ± 1.83 and 5.87 ± 1.81 days, respectively. Faropenem was administered twice daily in 309 patients and thrice daily in 656 patients. Clinical cure was achieved in 505 patients (52.33%), while 460 (47.67%) showed improvement. Among patients with available laboratory data, elevated baseline CRP and WBC values normalized in the majority at follow-up (CRP: 88%; WBC: 84%). No major adverse events were reported.
Conclusion: Faropenem demonstrated excellent real-world effectiveness and safety in paediatric URTIs. Consistent clinical improvement and normalization of inflammatory markers support its role as a well-tolerated therapeutic option in this population.
Key words: Oral carbapenem, Real-world data, Clinical outcomes, Inflammatory biomarkers